ADORA3 and hepatoblastoma: In detail, we performed cell-line drug response and viability assays on the human HEPG2 hepatoblastoma cell line for CGS-15943, an ADORA2A and ADORA1 inhibitor, which is reported to act against multiple adenosine receptors (Figure 6C), and MRS-1220, an ADORA3 and ADORA2B inhibitor.